Geron (NASDAQ:GERN) Issues Earnings Results

Geron (NASDAQ:GERN) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02, Zacks reports. Geron had a negative net margin of 46.65% and a negative return on equity of 28.86%.

Here are the key takeaways from Geron’s conference call:

• Rytelo Q1 net revenue was $61.8M (up 31% YoY, 8% QoQ), demand grew ~6% QoQ, footprint expanded to ~1,450 prescribing accounts, and management says it is on track for 2026 revenue guidance of $220–$240M.
• The phase III IMpactMF trial is fully enrolled with an interim overall‑survival event trigger expected in H2 2026, and management says a positive interim could materially strengthen imetelstat’s disease‑modifying profile and support broader MDS uptake.
• Geron is evaluating multiple go‑to‑market models for Europe (not pursuing a large internal build‑out), is conducting HTA/pricing work, and expects to announce its European commercial plan by year‑end.
• Gross‑to‑net deductions rose to 21% (from 13% a year ago) due to increased 340B utilization and GPO contracting and are expected to remain in the low‑to‑mid 20s for 2026, which pressures realized net revenue.
• Total operating expenses declined ~9% YoY to $50.4M in Q1 and management reiterated Opex guidance of $230–$240M; cash was ~$341M at quarter end after planned bonus, severance and CMC investments.

Geron Stock Performance

Shares of NASDAQ:GERN traded down $0.07 during trading hours on Wednesday, hitting $1.58. The stock had a trading volume of 21,455,098 shares, compared to its average volume of 15,212,574. The stock’s fifty day simple moving average is $1.60 and its 200 day simple moving average is $1.43. Geron has a 1-year low of $1.04 and a 1-year high of $2.01. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -12.15 and a beta of 0.68. The company has a debt-to-equity ratio of 0.53, a quick ratio of 3.62 and a current ratio of 4.66.

Key Geron News

Here are the key news stories impacting Geron this week:

• Positive Sentiment: Q1 commercial performance: RYTELO® net product revenue was $51.8M (up ~8% sequentially) and Geron beat revenue and EPS consensus modestly — signs of growing product traction. Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: Guidance maintained: management reiterated 2026 RYTELO net product revenue guidance of $220–$240M, giving investors forward revenue visibility. Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: Strong liquidity: the company closed the quarter with ~$341M in cash and marketable securities, lowering near-term financing risk. Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
• Neutral Sentiment: Management engagement: Geron announced executive and board additions and scheduled investor presentations (Bank of America conference May 12), which may improve investor access and visibility over coming weeks. Geron Plans to Present at Upcoming Investor Conferences
• Negative Sentiment: Profitability remains a concern: Geron reported a GAAP loss ($0.01) for the quarter and continues to show negative margins and ROE despite the beat, keeping path-to-consistent profitability uncertain. Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
• Negative Sentiment: Expense vs. revenue dynamics: management expects total operating expenses of $230–$240M versus revenue guidance of $220–$240M — at the midpoint this leaves a narrow gap and raises investor sensitivity to sales execution and margin leverage. Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

Analyst Upgrades and Downgrades

Several brokerages have recently commented on GERN. TD Cowen reaffirmed a “buy” rating on shares of Geron in a research report on Thursday, January 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Geron in a research report on Monday, April 27th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Geron currently has an average rating of “Hold” and an average price target of $2.17.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in GERN. Caitong International Asset Management Co. Ltd increased its holdings in shares of Geron by 3,307.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 24,410 shares in the last quarter. Amundi acquired a new stake in shares of Geron during the 4th quarter valued at $38,000. Franklin Resources Inc. bought a new stake in shares of Geron during the 3rd quarter worth $45,000. Cibc World Markets Corp acquired a new position in shares of Geron in the 4th quarter worth $48,000. Finally, Atom Investors LP raised its position in shares of Geron by 137.0% during the fourth quarter. Atom Investors LP now owns 37,341 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 21,588 shares during the period. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.